Arrowhead Pharmaceuticals, Inc. (0HI3.L)

22,25 -0,87 (-3,76%) Alla chiusura: 06:44PM BST

Arrowhead Pharmaceuticals, Inc.

177 East Colorado Boulevard
Suite 700
Pasadena, CA 91105
United States
626 304 3400
https://arrowheadpharma.com

Settore/i: 
Settore: 
Impiegati a tempo pieno: 525

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Christopher R. Anzalone Ph.D.	CEO, President & Director	1,6M	5,26M	1969
Mr. Kenneth A. Myszkowski	Chief Financial Officer	834,34k	N/D	1966
Mr. Patrick O'Brien J.D., PharmD	COO, General Counsel & Secretary	835,14k	990,4k	1964
Dr. James C. Hamilton M.D., MBA	Chief of Discovery & Translational Medicine	762,14k	N/D	1978
Dr. Mark M. Davis Ph.D.	Founder and Founder & Director of Insert Therapeutics Inc & Calando	N/D	N/D	N/D
Dr. Vincent Anzalone CFA	Head of Investor Relations & VP	N/D	N/D	N/D
Mr. Howard Lovy	Director of Communications	N/D	N/D	N/D
Dr. Bruce D. Given M.D.	Chief Medical Scientist	486,31k	5,93M	1954
Dr. Mark Seefeld	Head of Toxicology & VP	N/D	N/D	1954
Ms. Tracie Oliver	Chief Commercial Officer	449,58k	N/D	1962

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

Governance aziendale

L'ISS Governance QualityScore di Arrowhead Pharmaceuticals, Inc. al 1 aprile 2024 è 4. I criteri di valutazione fondamentali sono revisione: 9; Consiglio di Amministrazione: 7; diritti degli azionisti: 1; retribuzione: 2.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.